About CareTech CareTech Holdings PLC is a leading provider of specialist social care services supporting around 5,000 adults and children with a wide range of complex needs in more than 550 day services the UK employing more than 10,500 staff; and an emerging presence in international markets. Committed to the highest standards of care and care governance, CareTech s innovative Care Pathway covers Foster care, Children s Services, Adults Services and Technology Solutions. CareTech, which was founded in 1993, began trading on the AIM market of the London Stock Exchange in October 2005 under the ticker symbol CTH. For further information please visit: www.caretech-uk.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and dist
Winsford, UK - 30 April 2021: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that the Annual Report and Accounts for the year ended 31 December 2020 and Notice of Annual General Meeting were posted to shareholders today and are available on the Investor Relations section of the Group s website. Annual General Meeting The Board continues closely to monitor the coronavirus pandemic and our priority at this time remains the health, safety and well-being of all of our stakeholders. As part of its monitoring, the Board has noted, in particular, the gradual easing of public health restrictions across England in line with the government s COVID-19 Response - Spring 2021 roadmap published in February 2021.
Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines, that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development. Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m
Guildford, UK - 29 April 2021: Ergomed plc (LSE: ERGO) ( Ergomed or the Company ), a company focused on providing specialised services to the pharmaceutical industry, today announces that Dr. Llew Keltner, M.D., Ph.D., will join the Board as a Non-Executive Director with immediate effect. The Company also announces that Non-Executive Director, Ian Johnson, is stepping down from the Ergomed Board to focus on his other Board roles. Dr. Keltner brings over 30 years of experience across the life sciences sector, holding various senior positions with a particular focus on oncology and rare diseases. He has extensive experience of public and private financings, M&A, the formation of strategic partnerships and numerous transactions in the CRO, biotech and pharma sectors. While Chairman of Raptor Pharmaceuticals Inc., a US rare disease company, he led multiple financing rounds, product launches and the eventual sale of the Company to Horizon Phar